<DOC>
	<DOCNO>NCT00634413</DOCNO>
	<brief_summary>The purpose study assess tolerability efficacy inhale theophylline ( ADC4022 ) marker pulmonary inflammation ( white blood cell ) induce sputum bronchial biopsy sample subject moderate severe Chronic Obstructive Pulmonary Disease ( COPD ) co-administered budesonide compare placebo .</brief_summary>
	<brief_title>Effect ADC4022 Co-Administered With Budesonide Pulmonary Inflammation Subjects With Moderate Severe COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Confirmed diagnosis COPD symptomatic least 2 year The subject moderate severe COPD , define American Thoracic Society European Respiratory Society The subject produce adequate sputum specimen induction The subject history ≥ 10pack year cigarette smoke The subject either ≤15 % increase ≤200 ml increase FEV1 predose follow fix dose bronchodilator therapy The subject able provide write , inform consent participate The subject experience respiratory tract infection and/or exacerbation COPD within 30 day The subject use systemic corticosteroid ( oral parenteral ) The subject receive long term oxygen therapy within 30 day The subject previous history diagnosis asthma The subject chest xray within past 12 month diagnostic active clinically significant disease COPD The subject history presence active tuberculosis , cystic fibrosis , bronchiectasis , lung cancer sarcoidosis clinically important lung diseases The subject radiation chemotherapy within previous 12 month The subject history anaphylaxis associate medicinal product The subject pregnant , intend become pregnant , breast feed The subject 's alcohol intake excessive . The subject participate another study ( market drug ) within 3 month start study ( investigational drug ) within 4 month start study . Other inclusion/exclusion criterion may also apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>COPD</keyword>
</DOC>